Humanised antibodies
AssigneeCelltech Limited
InventorsJohn Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
Life of this patent
Estimating the term…
Abstract
CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
Claims8
An antibody molecule having affinity for a predetermined antigen and comprising a composite heavy chain and a complementary light chain, said composite heavy chain having a variable domain including complementarity determining regions (CDRs), said variable domain comprising predominantly human acceptor antibody heavy chain framework residues, the remaining heavy chain residues corresponding to the equivalent residues in a donor antibody having affinity for said predetermined antigen, wherein, according to the Kabat numbering system, in said composite heavy chain:
- said CDRs comprise donor residues at least at residues 31 to 35, 50 to 58, and 95 to 102;
- and amino acid residues 6 23, 24, and 49 at least are donor residues, provided that said composite heavy chain does not comprise the amino acid sequence of SEQ ID NO:31.
Dependencies are inferred from the claim text.